AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver highly potent cancer-killing agents..
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible financial incentives from the Singapore government. London-listed AstraZeneca has been expanding into markets like China, Indonesia and India over the past few years in an effort to widen its supply chain.
AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.
Shares in AstraZeneca rose 5.2% to 11,942.00 pence.
AstraZeneca Plc’s AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a…
By Elena Vardon AstraZeneca sees its revenue and core earnings per share growing by double-digit percentages in 2024, the pharmaceuticals major said as it.